Central effects of ORL1 receptor ligands
Maslov, L.N.; Lishmanov, I.B.; Calo, G.; Ma, L.
Eksperimental'naia i Klinicheskaia Farmakologiia 66(5): 59-68
2003
ISSN/ISBN: 0869-2092 PMID: 14650219 Document Number: 552319
It has been discussed literature data on molecular structure of ORL1 receptor and its interaction with intracellular signal systems and neurotransmitters. Data on chemical structure of ORL1 receptor ligands and their central effects (nociception, locomotion, feeding, cognition) are presented.
Document emailed within 1 workday
Related Documents
Nechipurenko, I.D. 1984: Cooperation effects in binding of large ligands to DNA. II. Contact interactions between adsorbed ligands Molekuliarnaia Biologiia 18(4): 1066-1080Li, G.-c.; Zhang, B.-l.; Xia, J.-y.; Fang, Z.-J. 2015: Synthesis and receptor binding assay of indolin-2-one derivatives as dopamine D4 receptor ligands Die Pharmazie 70(8): 511-514
Ashwell, J.D.; Fox, B.S.; Schwartz, R.H. 1987: Use of a receptor competition assay to explore the interaction of the T cell antigen-specific receptor with its ligands Federation Proceedings 46(1): 183-189
Knoflach, F.; Drescher, U.; Scheurer, L.; Malherbe, P.; Mohler, H. 1993: Full and partial agonism displayed by benzodiazepine receptor ligands at recombinant gamma-aminobutyric acidA receptor subtypes Journal of Pharmacology and Experimental Therapeutics 266(1): 385-391
Saito, Y. 2001: Searching for neurotransmitters as cognate ligands of orphan G protein-coupled receptor: finding receptor for melanin-concentrating hormone Nihon Shinkei Seishin Yakurigaku Zasshi 21(3): 77-82
Laube, F. 2009: Mannose-6-phosphate/insulin-like growth factor-Ii receptor in human melanoma cells: effect of ligands and antibodies on the receptor expression Anticancer Research 29(4): 1383-1388
Spetea, M.; Asim, M.Faheem.; Noha, S.; Wolber, G.; Schmidhammer, H. 2013: Current κ opioid receptor ligands and discovery of a new molecular scaffold as a κ opioid receptor antagonist using pharmacophore-based virtual screening Current Pharmaceutical Design 19(42): 7362-7372
Anzini, M.; Cappelli, A.; Vomero, S.; Botta, M.; Cagnotto, A. 1990: 5-HT and benzodiazepine receptor ligands. III. Synthesis and receptor affinities of 1,2,4-triazolo[4',3':1,6]pyridazino[4,5-b]quinoline and 2,3-dihydro-9-phenyl-1H-pyrrolo[3,4-b]quinoline-1-one derivatives Farmaco 45(11): 1169-1179
Arnerić, S.P.; Long, J.P.; Williams, M.; Goodale, D.B.; Mott, J.; Lakoski, J.M.; Gebhart, G.F. 1983: RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist Journal of Pharmacology and Experimental Therapeutics 224(1): 161-170
Hahn, R.A.; Wardell, J.R.; Sarau, H.M.; Ridley, P.T. 1982: Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist Journal of Pharmacology and Experimental Therapeutics 223(2): 305-313
Medina, A.; Bodick, N.; Goldberger, A.L.; Mac Mahon, M.; Lipsitz, L.A. 1997: Effects of central muscarinic-1 receptor stimulation on blood pressure regulation Hypertension 29(3): 828-834
Pertwee, R.G. 1999: Pharmacology of cannabinoid receptor ligands Current Medicinal Chemistry 6(8): 635-664
Schäcke, H.; Rehwinkel, H. 2004: Dissociated glucocorticoid receptor ligands Current Opinion in Investigational Drugs 5(5): 524-528
Dereń-Wesołek, A.; Maj, J. 1993: Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex Polish Journal of Pharmacology 45(5-6): 467-480
Jensen, L.H.; Wätjen, F.; Honoré, T.; Hansen, J.B.; Engelstoft, M.; Schmiechen, R. 1988: Oxadiazolylimidazobenzodiazepines, a new class of benzodiazepine receptor ligands Advances in Biochemical Psychopharmacology 45: 209-217
Bourrie, B.; Bribes, E.; Derocq, J.-M.; Vidal, H.; Casellas, P. 2004: Sigma receptor ligands: applications in inflammation and oncology Current Opinion in Investigational Drugs 5(11): 1158-1163
Fisas, M.A.; Gutiérrez, B.; Fort, M.; Dordal, A.; García, C.; Farré, A.J. 1998: General pharmacological profile and effects of E-4716, a novel histamine receptor blocker, on the central nervous system Methods and Findings in Experimental and Clinical Pharmacology 20(3): 199-210
Kubinyi, H. 1998: Structure-based design of enzyme inhibitors and receptor ligands Current Opinion in Drug Discovery and Development 1(1): 4-15
Alexander, J.; Snoke, K.; Ruppert, J.; Sidney, J.; Wall, M.; Southwood, S.; Oseroff, C.; Arrhenius, T.; Gaeta, F.C.; Colón, S.M. 1993: Functional consequences of engagement of the T cell receptor by low affinity ligands Journal of Immunology 150(1): 1-7
Nevalainen, T. 2014: Recent development of CB2 selective and peripheral CB1/CB2 cannabinoid receptor ligands Current Medicinal Chemistry 21(2): 187-203